AD 5
| Code | Size | Price |
|---|
| TAR-T29633-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
AD 5 is a bioactive chemical.
CAS:
92455-12-4
Formula:
C12H13NO4
Molecular Weight:
235.239
Purity:
0.98
SMILES:
COc1ccc(CC(=O)NC(=C)C(O)=O)cc1
References
1. Nguyen TV, Crosby CM, Heller GJ, Mendel ZI, Barry ME, Barry MA. Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer. Oncolytic Virother. 2018 May 3;7:43-51. doi: 10.2147/OV.S155946. eCollection 2018. PubMed PMID: 29765912; PubMed Central PMCID: PMC5939883.
2. Zhang W, Fu J, Ehrhardt A. Novel vector construction based on alternative adenovirus types via homologous recombination. Hum Gene Ther Methods. 2018 May 14. doi: 10.1089/hgtb.2018.044. [Epub ahead of print] PubMed PMID: 29756505.
3. Jung SY, Kang KW, Lee EY, Seo DW, Kim HL, Kim H, Kwon T, Park HL, Kim H, Lee SM, Nam JH. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Vaccine. 2018 May 5. pii: S0264-410X(18)30598-X. doi: 10.1016/j.vaccine.2018.04.082. [Epub ahead of print] PubMed PMID: 29739720.
4. Li P, Feng F, Pan E, Fan X, Yang Q, Guan M, Chen L, Sun C. Scavenger receptor-mediated Ad5 entry and acLDL accumulation in monocytes/macrophages synergistically trigger innate responses against viral infection. Virology. 2018 Apr 19;519:86-98. doi: 10.1016/j.virol.2018.04.005. [Epub ahead of print] PubMed PMID: 29680370.